# Jaguar Health, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Jaguar Health, Inc.). ## Overview Jaguar Health, Inc. develops and commercializes plant-based prescription and non-prescription products for human and animal health, with a portfolio centered on crofelemer-based therapies and related botanical medicines. The company also uses licensing and partnership structures to extend its products and pipeline, including Mytesi, Canalevia-CA1, Gelclair, and early-stage botanical drug candidates through its Magdalena joint venture. ## Products & services • Mytesi human prescription drug sold through distributors and specialty pharmacies • Crofelemer-based pipeline for follow-on human indications • Canalevia-CA1 animal health product for companion animals • Neonorm Calf and Neonorm Foal botanical products for livestock • Gelclair U.S. commercialization rights under in-license agreement • Magdalena botanical CNS/mental health drug development platform - **Human prescription products** (55%) — Includes Mytesi, crofelemer-based follow-on indications, and licensed human therapies such as Gelclair. - **Animal health products** (25%) — Includes Canalevia-CA1 and Neonorm products sold for companion animals and livestock. - **License and royalty revenue** (15%) — Includes revenue from licensing arrangements such as the Gen territory agreement and other partner monetization. - **Early-stage pipeline and collaborations** (5%) — Includes Magdalena and other botanical drug development efforts that are not yet commercial revenue drivers. - Mytesi prescription therapy for human use - Crofelemer follow-on indications and pipeline assets - Canalevia-CA1 for companion animal health - Neonorm Calf and Neonorm Foal botanical products - Gelclair U.S. rights for oral mucositis treatment - Magdalena plant-based CNS and mental health candidates ## Customers Jaguar sells mainly to distributors, wholesalers, and specialty pharmacies, which then supply patients, veterinarians, and other end users. Its human-health customers are tied to prescription access and licensing partners, while its animal-health products are sold through distribution channels serving companion animal and livestock markets. The company also relies on collaboration and license counterparties to monetize parts of its pipeline and geographic rights. - **Distributors and wholesalers** (primary) — Buy Mytesi, Canalevia-CA1, and Neonorm products for onward sale into pharmacy and veterinary channels. - **Specialty pharmacies** (secondary) — Dispense Mytesi to patients under prescription and support access for niche human indications. - **Animal health channel partners** (secondary) — Purchase animal products for resale to veterinarians, livestock operators, and end customers. - **Licensees and collaboration partners** (primary) — Monetize territory rights or development assets and provide upfront or ongoing license revenue. - **Future pharmaceutical partners** (emerging) — Potential partners for crofelemer follow-on indications and Magdalena pipeline assets. - Distributors and wholesalers buying Mytesi and animal products - Specialty pharmacies dispensing human prescription therapies - License partners commercializing products in specific territories - Veterinary and livestock channels purchasing animal health products - Potential future pharma partners for pipeline out-licensing ## Geography Jaguar is headquartered in the United States and generates most of its operating activity there, including product commercialization, development, and licensing. The company also has international exposure through territory licensing, a U.K.-based in-license from Venture Life, and global rights around crofelemer and related assets. Its geographic footprint matters because commercialization, regulatory approval, and partner execution are all tied to country-specific market access and FDA oversight. - United States is the core operating and commercialization market - U.S. FDA approval and review timing are critical to pipeline value - International licensing expands reach without heavy foreign infrastructure - U.K.-based Venture Life is a source of licensed product rights - Global rights to crofelemer support future partnership optionality ## Strategy Jaguar is focused on extending the commercial life of crofelemer while building new plant-based drug opportunities through internal development and partnerships. Near-term priorities include supporting Mytesi and animal product sales, advancing pipeline indications, and using collaborations such as Magdalena to broaden the addressable market without fully funding every program internally. The company is also managing liquidity by seeking financing, partnerships, and license revenue to support ongoing development and commercialization. - **Advance crofelemer follow-on indications** (medium-term) — New indications could broaden the commercial opportunity beyond current products and create partnership value. - **Monetize through partnerships and licenses** (short-term) — Upfront fees, territory licenses, and collaboration economics can fund operations without full internal commercialization costs. - **Support existing product commercialization** (short-term) — Current product sales provide operating traction and validate the botanical drug platform. - **Preserve liquidity and capital access** (short-term) — The company has recurring losses and needs external funding to continue development and commercialization. - Expand crofelemer into follow-on human indications - Use partnerships to share development and commercialization risk - Grow Mytesi and animal product revenue through distribution channels - Advance Magdalena plant-based CNS and mental health candidates - Secure financing to support development and operating liquidity ## Risks Jaguar remains a development-stage pharmaceutical company with recurring losses, limited cash, and dependence on external financing, so execution and funding risk are central. Regulatory timing, especially at the FDA, can materially delay approvals and commercialization, while royalty obligations and minimum payments can pressure liquidity even if sales remain modest. The company also faces typical pharma risks around clinical success, product returns, pricing pressure, and manufacturing or supply-chain costs. - **Liquidity shortfall and financing dependence** [high] — The company has recurring operating losses and may not fund its plan from existing cash. - **FDA review and approval delays** [high] — Regulatory disruptions can slow submissions, meetings, inspections, and approvals. - **Minimum royalty payment obligations** [high] — Royalty interests require payments even if product sales are insufficient. - **Clinical development failure** [high] — Pipeline assets depend on positive human trial and proof-of-concept results. - **Cost inflation and margin pressure** [medium] — Higher raw material, labor, and distribution costs can compress gross margins. - Recurring losses and low cash create going-concern and dilution risk - FDA delays can slow approvals and reduce pipeline value - Minimum royalty payments can strain liquidity even without strong sales - Clinical and regulatory outcomes remain uncertain for pipeline assets - Inflation raises raw material, labor, and distribution costs - Product returns and demand variability can affect reported revenue ## Accounting Revenue recognition is split between product sales and license revenue, so timing depends on shipment, distributor activity, and contract terms. The company also uses estimates for returns, fair value changes on financial instruments, debt extinguishment, and stock-based compensation, all of which can move reported earnings materially in a small revenue base. Because Jaguar is loss-making and capital constrained, judgments around royalty liabilities, financing instruments, and potential impairments are especially important. - **Revenue recognition for product and license revenue** — Quarterly revenue mix can be volatile - **Sales returns reserve** — Can reduce reported net revenue - **Fair value measurement of financial instruments** — Can create non-cash earnings volatility - **Debt extinguishment accounting** — Affects operating loss comparability - **Royalty obligations and minimum payments** — Important for liquidity analysis and covenant-like pressure - Product vs license revenue timing affects quarterly comparability - Returns reserves rely on historical patterns and can shift revenue - Fair value changes on financial instruments can swing earnings - Debt extinguishment gains or losses affect non-operating results - Stock-based compensation and non-cash interest affect loss metrics --- *Last updated: 2026-04-28T20:18:55.926947+00:00*